麦圈 Medprober

https://www.medprober.com/麦圈 Medprober泌尿外科文献速递与临床资讯 2026-10-25T13:44:38+08:00 Medprober https://www.medprober.com/ Jekyll © 2026 Medprober /assets/img/favicons/favicon.ico /assets/img/favicons/favicon-96x96.png VOLGA 研究：度伐利尤单抗联合维恩妥尤单抗改善肌层浸润性膀胱癌的无事件生存和总生存2026-10-25T09:17:00+08:00 2026-10-25T09:17:00+08:00 https://www.medprober.com/posts/volga-durvalumab-enfortumab-vedotin-mibc-esmo-2026/ Medprober

III 期 VOLGA 试验显示，围手术期度伐利尤单抗联合新辅助维恩妥尤单抗治疗顺铂不耐受的肌层浸润性膀胱癌，无事件生存风险降低 49%、死亡风险降低 42%，2 年无事件生存率为 64% 对 45%。

Enrollment goal met in trial of individualized ADT/RT for high-risk prostate cancer2025-09-26T14:40:12+08:00 2025-09-26T14:40:12+08:00 https://www.medprober.com/posts/enrollment-goal-met-in-trial-of-individualized-adt-rt-for-high-risk-prostate-cancer/ Medprober

高风险前列腺癌的个体化ADT/RT治疗试验已满员。为评估高风险前列腺癌患者是否可以根据Decipher基因检测结果分配到减轻或加强的并发激素治疗和放射治疗 regimen。该试验 enroll 2478名成人患者，患者将进行Decipher基因检测，以确定是否将分配到减轻或加强治疗。该试验旨在改善高风险前列腺癌患者的生活质量和结果，同时根据每个个体的需要分配治疗。来源: urologytimes 原文链接：原文参考文献 NRG Oncology PREDICT-RT study completes patient accrual, tests individualized concurrent therapy and radiation for high-risk prostate cancer. News release. NRG Oncology. Septemb...

First Assist: The Historical Context of NMIBC, with Kamal Pohar, MD2025-09-19T10:00:00+08:00 2025-09-19T10:00:00+08:00 https://www.medprober.com/posts/first-assist-the-historical-context-of-nmibc-with-kamal-pohar-md/ Medprober

非muscle浸透性膀胱癌（NMIBC）的历史背景和管理策略。NMIBC的管理和 surveillance strategy已经发生了很大的变化。BCG是最早被用于治疗NMIBC的药物，它的dosage和维持方案也已经被确定。 Surveillance strategies, repeat transurethral resection of the bladder tumor for T1 tumors, and the introduction of enhanced cystoscopy techniques like blue light and narrow band imaging have proven impact on tumor detection and recurrence。Biomarkers like traditional cytology, UroVy...

SURE procedure linked with lower healthcare utilization vs URS2025-09-11T17:25:46+08:00 2025-09-11T17:25:46+08:00 https://www.medprober.com/posts/sure-procedure-linked-with-lower-healthcare-utilization-vs-urs/ Medprober

kidney stones, SURE procedure, ureteroscopy, healthcare utilization, stone clearance, residual stone volume 来源: urologytimes 原文链接：原文参考文献 Calyxo debuts reverse deflection CVAC System and reveals groundbreaking two-year ASPIRE data at WCET 2025, underscoring the technology’s role in advancing endourology. News release. Calyxo. September 11, 2025. Accessed September 11, 2025. https://www.bu...

Updated BOND-003 data support durability of cretostimogene grenadenorepvec in NMIBC2025-09-05T13:50:08+08:00 2025-09-05T13:50:08+08:00 https://www.medprober.com/posts/updated-bond-003-data-support-durability-of-cretostimogene-grenadenorepvec-in-nmibc/ Medprober

高风险非muscle invasvie bladder cancer（NMIBC）患者中的BCG无响应性治疗，cretostimogene grenadenorepvec的耐用性和安全性均有实证。根据BOND-003试验的最新数据，12个月内的完全响应（CR）患者中，有90%仍在CR状态于24个月；24个月的CR率为41.8%。该药物的安全性良好，无grade 3或更高治疗相关不良事件（TRAEs）的报告。该药物的耐用性和安全性使其有望成为bladder cancer患者的突破性治疗选择。来源: urologytimes 原文链接：原文参考文献 CG Oncology continues to demonstrate best-in-disease durability and tolerability in BOND-003 cohort C; additional...